De novo drug design.
Computer-assisted molecular design supports drug discovery by suggesting novel chemotypes and compound modifications for lead structure optimization. While the aspect of synthetic feasibility of the automatically designed compounds has been neglected for a long time, we are currently witnessing an increased interest in this topic. Here, we review state-of-the-art software for de novo drug design with a special emphasis on fragment-based techniques that generate druglike, synthetically accessible compounds. The importance of scoring functions that can be used to predict compound reactivity and potency is highlighted, and several promising solutions are discussed. Recent practical validation studies are presented that have already demonstrated that rule-based fragment assembly can result in novel synthesizable compounds with druglike properties and a desired biological activity.
Hartenfeller
Markus
M
Institute of Organic Chemistry and Chemical Biology, Johann Wolfgang Goethe University, Frankfurt, Germany.
Schneider
Gisbert
G
D000465:Algorithms; D017076:Computer-Aided Design; D015195:Drug Design; D008958:Models, Molecular; D015394:Molecular Structure; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis* / Q000737:chemistry; D015203:Reproducibility of Results; D012984:Software
D004364:Pharmaceutical Preparations